




>>Entry Name: Octreotide, BAN, INN, USAN

Synonym(s): Longastatina. Samilstin. Sandostatin. SMS 201-995



CAS Registry Number: 83150-76-9

Related CAS Registry Numbers(s): 88495-44-7 95189-74-5

Molecular Formula: C₄₉H₆₆N₁₀O₁₀S₂

Molecular Weight: 1019.253

Accurate Mass: 1018.44048

Percentage Composition: C 57.74%; H 6.53%; N 13.74%; O 15.70%; S 6.29%

Use/Importance: Growth hormone secretion inhibitor. Opiate antagonist used in treatment of GI tract tumours; also used in the treatment of acromegaly

Development Status: Launched 1988

Optical Rotation: $[\alpha]_D^{20} -42$ (c, 0.5 in AcOH)

Other Data: Opt. isomers also known

>>Derivative: Acetate salt (1:x)

Synonym(s): Octreotide acetate, USAN

CAS Registry Number: 79517-01-4

Hazard & Toxicity: LD₅₀ (rat, ivn) 18 mg/kg

>>Derivative: 4,4'-Methylenebis(3-hydroxy-2-naphthoate) salt

Synonym(s): Octreotide pamoate, USAN

CAS Registry Number: 135467-16-2

Physical Description: Yellow powder

Optical Rotation: $[\alpha]_D^{20} +7.5$ (c, 0.35 in DMF)

References:

- Bauer, W. *et al.*, *Life Sci.*, 1982, **31**, 1133, (*props*)
Wynants, C. *et al.*, *Int. J. Pept. Protein Res.*, 1985, **25**, 608; 615, (*pmr, conformn*)
U.S. Pat., 1985, Sandoz, 4 395 403; *CA*, **95**, 187679e, (*synth*)
Pless, J. *et al.*, *Int. Congr. Ser. Excerpta Med.*, 1986, **683**, 319, (*pharmacol*)
Longnecker, J.P., *Drug Intell. Clin. Pharm.*, 1988, **22**, 99, (*rev*)
Katz, M.D. *et al.*, *Clin. Pharm.*, 1989, **8**, 255, (*rev*)
Battershill, P.E. *et al.*, *Drugs*, 1989, **38**, 658, (*rev*)
Metab., Clin. Exp., (Eds. Harris, A.G. *et al.*), *Suppl. 2*, 1992, **41**, (*rev*)
Harris, A.G. *et al.*, *Eur. J. Med.*, 1993, **2**, 97, (*rev*)
Martindale, The Extra Pharmacopoeia, 30th edn., *Pharmaceutical Press*, 1993, 958
U.S. Pat., 1996, Sandoz, 5 538 739; *CA*, **125**, 177407, (*pamoate*)
Gillis, J.C. *et al.*, *Drugs*, 1997, **54**, 681-699, (*rev*)